Here’s what you need to know:
1. Galmed Pharmaceuticals develops treatments for liver diseases. Its current product candidate is an oral drug called Aramchol.
2. Prior to joining Galmed Pharmaceuticals, Dr. Hayardeny worked in the global research and development division of Teva Pharmaceuticals, another Israeli pharmaceutical company. She served as the head of research scientific affairs.
3. Dr. Hayardeny earned her doctorate degree from Tel Aviv University’s Sackler School of Medicine and her MBA from Tel Aviv University’s Recanati Business School.
More articles on gastroenterology and endoscopy:
Gastroenterologists, IBD patients may benefit from nutritional care resources: 5 study insights
invendo medical GmbH receives FDA clearance for invendoscopy E200 System: 5 notes
Gene mutation may explain high CRC incidence, mortality in black patients: 4 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
